• The Korean Journal of Applied Statistics
• /
• v.11 no.2
• /
• pp.205-219
• /
• 1998

Statistical analyses have been perf7rm7d to find factors affecting chronic renal allograft dysfunction for 114 renal transplanted patients. Renal function was evaluated using serum creatinine values every three months during 1 year to 5 years after transplantation. Statistical models for the repeated measures were considered to evaluate factors affecting the reciprocal of serum creatinine values. This paper focuses on some common problems on the choice of correlation matrices occurred in the analysis of repeated measures.

• The Science & Technology
• /
• v.31 no.3 s.346
• /
• pp.92-93
• /
• 1998

명지대 천연 신기능 소재개발 센터는 국내최초로 비타민A의 제조기술을 확립한데 이어 이번엔 '베타 카로틴'의 혁신적인 제조기술의 완성단계에 이르러 세계의 주목을 받고 있다. 베타카로틴은 비타민A를 제공해주는 전위체로 면역증진 및 항산화제로서의 효과가 큰 물질이다. 이 개발센터는 항균활성을 갖는 천도 만들어 병원과 일반 위생업계의 관심을 모으고 있다.

• Childhood Kidney Diseases
• /
• v.8 no.1
• /
• pp.18-25
• /
• 2004

Purpose : Alport syndrome is clinically characterized by hereditary progressive nephritis causing ESRD with irregular thickening of the GBM and sensory neural hearing loss. The mutations of type IV collagen gene(COL4A5) located on the long arm of X chromosome is considered responsible for most of the structural abnormalities in the GBM of Alport patients. Since no definite clinical prognostic predictor has been reported in the disease yet, we designed this study to evaluate the significance of genetic polymorphism of the angiotensin converting enzyme in children with Alport syndrome as a prognostic factor for disease progression. Methods : ACE I/D genotype were examined by PCR amplification of the genomic DNA in 12 patients with Alport syndrome and 12 of their family members. Alport patients were divided into two groups; the conservative group, those who had preserved renal function for more than 10 years of age, the early CRF group, those who had progressed to CRF within 10 years of age. Results : The mean age of onset was $3.45{\pm}2.4$ years in the conservative group, $4.4{\pm}1.2$ years in the early CRF group. Sex ratios were 5:3 and 2:1 in each group. Among 12 cases of patients, 4 cases were in early CRF group and their mean duration of onset to CRF was 4.5 yews(8.9 years of age). Eight patients(67%) were in the conservative group and they had normal renal function for more than 10 years of age(mean duration of renal preservation was 10.6 years). The incidence of II type ACE gene were in 25.0%(3 cases), ID type in 41.7%(5 cases), DD type in 33.3%(4 cases). There was no significant difference between Alport patient and normal control(II type 44.3%, ID type 40.9%, DD type 14.8%). The incidence of DD type of early CRF group were higher than that of the conservative group(75% vs 12.5%)(p<0.05). There was no difference in ACE gene polymorphism between normal Alport family members and control group. Conclusion : Even though there was no significant difference of ACE polymorphism between Alport patients and the normal control group, the incidence of DD type is significantly increased in early CRF group which means DD type of ACE polymorphism has a possibility of being a predictor for early progression to CRF in Alport patients.

• Korean Journal of Clinical Pharmacy
• /
• v.16 no.1
• /
• pp.1-8
• /
• 2006

Methotrexate(MTX)는 소아 골육종 환자에서 $12g/m^2$의 고용량을 사용하고 있다. 현재, 소아 골육종 환자에서 신기 능에 따른 고용량 MTX의 임상 약동학은 연구되어 있지 않다. 따라서 본 연구에서는 신기능에 따른 MTX 약동학을 이용하여 구내염을 최소화하는 방법을 제시하고자 하였다. 방법: 환자들의 의무기록지를 후향적 방법으로 검토하였다. 한 병원에서 골육종으로 진단받고, 치료 받은 환자들을 대상으로 정상 신기능군과 비정상 신기능군으로 나누었다. 두 군에 MTX 투여 후 혈중 농도를 각각 비교하였고, 최고 혈중농도도 비교하였다. 혈중 농도와 구내염의 관련성, CL, AUC와 구내염의 상관관계를 분석하였다. 각 군의 terminal half-life, CL, Vss의 평균과 mea residence time(MRT)의 평균을 구하였고, 두 군간 각각을 비교하였다 $({\alpha}=0.05)$. 결과: 환자는 6명이었고, 평가 가능한 총 MTX 투여 회수는 34회였다. MTX 투여 후 최고혈중 농도, 24,48 시간의 혈중농도는 통계적으로 유의성 있는 차이가 있었고, 72,96 시간에서의 농도는 두 군간 유의성이 없었다. 각 군에서 혈중농도와 구내염의 상관관계, 그리고 CL, AUC와 구내염의 상관관계는 발견되지 않았다. Vss를 제외한 모든 파라미터들(terminal half-life, CL, MRT)은 통계적으로 유의성 있는 차이가 있었다. 결론: 비정상 신기능 군에서 MTX 투여 시작 후 24, 48 시간에서의 혈중농도가 더 높고, 변동이 심했다. 또한 MTX의 CL는 감소했고, 혈중농도는 증가하였다. 이러한 사실로 MTX 투여 전 후 혈중 크레아티닌이나 또는 크레아티닌 청소율 모니터링이 필요하다는 것을 알 수 있으며, MTX 투여가 끝난 직후 그리고 그 이후 24 시간 간격으로 혈중 농도를 측정해야함을 알 수 있다.

• Journal of Chest Surgery
• /
• v.31 no.1
• /
• pp.32-39
• /
• 1998

High-dose aprotinin(Hammersmith regimen) has been widely used for years to control postoperative bleeding and reduce blood consumption in cardiac surgery but had known to cause some side-effects and had disadvantage in cost-effectiveness. The prospective controlled study of 33 patients undergoing cardiopulmonary bypass was performed to evaluate the efficacy for reducing postoperative bleeding and unfavorable effects of low-dose aprotinin. The level of hemoglobin and platelet in the blood and the amount of postoperative bleeding were assessed preoperatively, and postoperatively for the study of hemostatic function. The level of BUN and serum creatinine in the blood, levels of urine creatinine, total protein, albumin, alpha-1-microglobulin and creatinine clearance were assessed before and after the operation for the study of renal function. The aprotinin group had a significant reduction in chest tube drainage; 243$\pm$ 123 ml versus 406$\pm$303 ml(P=0.037) during 6 hours immediate-postoperatively, 494$\pm$358 ml versus 869$\pm$570 ml(P=0.045) during 24 hours postoperatively. The ratio of alpha-1-microglobulin/creatinine and microalbumin/creatinine in the urine were slightly increased in the aprotinin group postoperatively in comparison with the control group but there were no statistically significant difference(55$\pm$23 versus 24$\pm$10 in the alpha-1-microglobulin/creatinine, 56$\pm$19 versus 38$\pm$25 in the microalbumin/creatinine at post- operative 3rd day). There were no significant difference between two groups in other parameters of renal function, too. This study showed that low-dose aprotinin is an effective means of reducing postoperative bleeding without inducing significant renal dysfunction.

• The monthly packaging world
• /
• s.99
• /
• pp.164-167
• /
• 2001

• The Microorganisms and Industry
• /
• v.19 no.1
• /
• pp.63-67
• /
• 1993

• The monthly packaging world
• /
• s.96
• /
• pp.117-123
• /
• 2001

• Ceramist
• /
• v.2 no.1
• /
• pp.27-36
• /
• 1999

• Proceedings of the Korean Institute of Surface Engineering Conference
• /
• 2001.11a
• /
• pp.1-1
• /
• 2001

21세기의 신물질로 알려져 있는 플라즈마는 기체에 에너지를 가해 형성되는 높은 에너지(수십만도)의 이옹화된 기체의 집합체로 최근 이러한 플라즈마를 이용하여 고부가가치의 신기 능 제품개발에 널리 활용되고 있다. 플라즈마를 이용한 신기능 표면처리 기술개발이 가속 화됨에 따라 자동차, 기계, 전자, 에너지, 환경 산엽둥 전 산업 분야에 그 응용범위가 광범위 하게 확대 되고 있으며 이에 따른 핵심 연구개발도 최근 매우 중요시 되고 있다. 본 발표에서는 이라한 최끈 플라즈마 기술의 발전동향, 응용현황 및 향후 기술 확산을 위한 핵심 연구 방향에 대해 고찰하고저 한다.